Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users

American Journal of Gastroenterology

Volumn 103, Issue 2, 2008, Pages 323-332

  Abraham, Neena S ^a,b,f   Hartman, Christine ^a   Castillo, Diana ^a   Richardson, Peter ^a   Smalley, Walter ^c,d,e  

^a Houston Center for Quality of Care and Utilization Studies   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e Valley VA GRECC   (United States)

^f MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CHOLINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; PIROXICAM; PROTON PUMP INHIBITOR; SALICYLIC ACID DERIVATIVE; SALSALATE; SEROTONIN UPTAKE INHIBITOR; STATINE DERIVATIVE; STEROID; SULINDAC; TOLMETIN; UNINDEXED DRUG;

AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STOMACH PROTECTION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; FEMALE; GASTROINTESTINAL DISEASES; GUIDELINE ADHERENCE; HUMANS; MALE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK;

EID: 39049165653     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01595.x     Document Type: Article

References (40)

1. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence based guidelines for the prescription of non-steroidal anti-inflammatory drugs. Gastroenterology 2005 129 : 1171 8.
2. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995 40 : 1345 50.
3. Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 1999 13 : 119 22.
4. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988 109 : 359 63.
5. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991 114 : 257 63.
6. Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006 4 : 1337 45.
7. Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003 42 (Suppl 3 iii23 31.
8. Abraham NS, Cohen DC, Rivers B, et al. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther 2006 24 : 299 306.
9. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 45 : 613 9.
10. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997 127 : 757 63.
11. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998 17 : 2265 81.
12. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: Concepts and analytical approaches. Annu Rev Public Health 2000 21 : 121 45.
13. Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003 18 : 1137 47.
14. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006 101 : 701 10.
15. Chan FK. Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin. Drugs 2006 66 (Suppl 1 23 8.
16. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002 347 : 2104 10.
17. Rahme E, Bardou M, Dasgupta K, et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: A retrospective cohort study. Rheumatology (Oxford) 2007 46 : 265 72.
18. Pilotto A, Franceschi M, Leandro G, et al. NSAID and aspirin use by the elderly in general practice: Effect on gastrointestinal symptoms and therapies. Drugs Aging 2003 20 : 701 10.
19. Pilotto A, Franceschi M, Leandro G, et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: The role of gastroprotective drugs. Aging Clin Exp Res 2003 15 : 494 9.
20. Chan FK, Wong VW, Suen BY et al. Proton pump inhibitor plus a COX-2 inhibitor for the prevention of recurrent ulcer bleeding in patients with arthritis: A double-blind, randomized trial. Gastroenterology 2006 130 (Suppl 2 A105.
21. Garcia Rodriguez LA, Barreales TL. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007 132 : 498 506.
22. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006 55 : 1731 8.
23. Cryer B. A COX-2-specific inhibitor plus a proton-pump inhibitor: Is this a reasonable approach to reduction in NSAIDs' GI toxicity? Am J Gastroenterol 2006 101 : 711 3.
24. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991 115 : 787 96.
25. Garcia Rodriguez LA, Walker AM, Perez GS. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: A cohort study. Epidemiology 1992 3 : 337 42.
26. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995 141 : 539 45.
27. Lapane KL, Spooner JJ, Mucha L, et al. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 2001 49 : 577 84.
28. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004 20 : 1091 7.
29. Taha AS, Angerson W, Nakshabendi I, et al. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs - influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther 1993 7 : 41 5.
30. Lipscomb GR, Campbell F, Rees WD. The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1997 11 : 907 12.
31. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002 123 : 1006 12.
32. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988 26 : 814 23.
33. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997 50 : 105 16.
34. Cox ER, Frisse M, Behm A, et al. Over-the-counter pain reliever and aspirin use with a sample of long-term cyclooxygenase 2 users. Arch Intern Med 2004 164 : 1243 5.
35. Lewis SC, Langman MJS, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: A meta-analysis based on individual patient data. Br J Clin Pharmacol 2002 54 : 320 6.
36. Lewis JD, Bilker WB, Brensinger C, et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: Relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002 97 : 2540 9.
37. Lewis JD, Kimmel SE, Localio AR, et al. Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 2005 129 : 1865 74.
38. Rich M, Scheiman JM. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: Mechanisms and prevention. Semin Arthritis Rheum 2000 30 : 167 79.
39. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology. Am J Med 1998 105 : 3S 9S.
40. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997 336 : 1054 8.